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Spontaneous self-terminating atrial fibrillation (AF) is one of the most common heart rhythm disorders, yet the regulatory
molecular mechanisms underlying this syndrome are rather unclear. MicroRNA (miRNA) transcriptome and expression of
candidate transcription factors (TFs) with potential roles in arrhythmogenesis, such as Pitx2, Tbx5, and myocardin (Myocd), were
analyzed bymicroarray, qRT-PCR, andWestern blotting in left atrial (LA) samples from pigs with transitory AF established by right
atrial tachypacing. Induced ectopic tachyarrhythmia caused rapid and substantial miRNA remodeling associated with a marked
downregulation of Pitx2, Tbx5, and Myocd expression in atrial myocardium. The downregulation of Pitx2, Tbx5, and Myocd was
inversely correlated with upregulation of the corresponding targeting miRNAs (miR-21, miR-10a/10b, and miR-1, resp.) in the LA
of paced animals. Through in vitro transient transfections of HL-1 atrial myocytes, we further showed that upregulation of miR-21
did result in downregulation of Pitx2 in cardiomyocyte background. The results suggest that immediate-early miRNA remodeling
coupled with deregulation of TF expression underlies the onset of AF.
1. Introduction
Atrial fibrillation (AF), a heart rhythm disorder dubbed as
“the epidemic of the 21st century” [1], represents nowadays
a serious clinical problem making the development of novel
treatment approaches highly desirable (recently reviewed
in [2]). AF is generally considered to be a progressive
condition, occurring first in a paroxysmal form (short-lived
self-terminating episodes) and then in persistent and eventu-
ally long-lasting permanent forms. Recent growing evidence
indicates that the underlying molecular mechanisms are dis-
tinct in each form of AF [3, 4]. Proarrhythmogenicmolecular
remodeling, broadly defined as any change in atrial gene
regulation that promotes atrial conduction disturbances, is
potentially crucial for unraveling the onset mechanisms of
atrial tachyarrhythmias.
There is emerging evidence that microRNAs (miRNAs)
can modulate a diverse spectrum of cardiac functions
through their ability to remodel cardiac transcriptional cir-
cuits (reviewed in [5–7]). The tight regulation of the levels
of miRNAs is critical for maintaining normal physiological
conditions, and dysregulated miRNA levels contribute to
the development of heart diseases (reviewed in [8–10]). In
relevance to this study, miRNAs have been demonstrated
to be essential in regulating atrial excitability and can be
involved, directly or indirectly, in increased atrial arrhythmo-
genicity and AF (reviewed in [11–15]). In this context, there is
growing evidence regarding the aberrant miRNA expression
in chronic AF conditions in patients [16–22], while only a
few papers have focused on miRNA transcriptomic profiling
of atrial samples from patients with paroxysmal AF [23,
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24]. Specifically, these papers demonstrated that a miRNA-
mediated imbalance in the gonadotropin releasing hormone
receptor/p53 [23] and metalloproteinase/inhibitor [24] path-
ways may potentially be involved in atrial remodeling. As
it is mentioned in the reports, fibrillating atrial samples
were collected during cardiac surgery in hypertonic patients
[23] or in patients with long-lasting (years) paroxysmal
AF [24]. Each of these clinical conditions is known to be
associated with a chronic atrial stretch and consequent atrial
structural remodeling. In this sense, left atrial enlargement
was observed in patients in the study by [24].
Although these studies provide evidence in support of
the importance of miRNAs in long-lasting AF, the use of
miRNA expression profiling as a tool to assess the very-early
atrial remodeling in animal models of self-terminating atrial
tachyarrhythmias (resembling early-onset lone paroxysmal
AF in humans) is still missing. It is important to highlight
that the left (LA) and right (RA) atria have different suscep-
tibilities towards developing arrhythmias, given the fact that
the pulmonary veins and surrounding myocardial regions of
the LA constitute the most frequent foci of AF initiation.
In the current study, we report the changes in miRNA
expression in the LA in response to ectopic tachyarrhyth-
mia episodes induced by short-term atrial pacing in pigs.
38 microRNAs were differentially expressed, 18 of which
were upregulated in the LA of paced versus sham (control)
animals. In addition, we identified expression differences for
novel miRNAs that have not previously been annotated as
either cardiac- or AF-associated.
Alterations in atrial miRNAs can contribute to tran-
scription factor (TF) deregulations underlying early atrial
remodeling. Genome-wide association studies and other
approaches have identified the TFs, Pitx2 and Tbx5 as
candidate genes linked to susceptibility for early develop-
ment of AF (reviewed in [41, 42]) and myocardin (Myocd)
as a transcription cofactor linked with LA functional and
structural remodeling [43]. Interestingly, Pitx2, Tbx5, and
Myocd expression is markedly downregulated in the LA in
response to ectopic tachyarrhythmia. Particularly intriguing
is that the downregulation of these TFs inversely correlates
with upregulation of the corresponding targeting miRNAs in
the LA of paced animals.
2. Materials and Methods
2.1. Animals and Experimental Design. “Large white” 3-
month-old pigs were obtained from a local commercial
breeder (La Corun˜a, Spain) and randomly divided into two
groups: (1) sham (𝑛 = 5; mean body weight, 25.2±1.2 kg) and
(2) atrial tachypacing (𝑛 = 5;mean bodyweight, 25.7±0.8 kg).
A close-chest tachyarrhythmia model was established in ani-
mals via rapid atrial electrical stimulation with a controlled
ventricular response rate. To control anaesthesia, ventilation,
and oxygenation, ECG, heart rhythm, and blood pressure
were continuously monitored. The right femoral vein was
dissected and cannulated with a multielectrode catheter
(Medtronic, Minneapolis, USA) connected with an external
pulse stimulator (A-M Systems, UK) for programmed pacing
rates. Under fluoroscopic guidance, the catheter was passed
into the right atrium (Figure 1). To avoid tachycardia-induced
ventricular dysfunction (ventricular arrhythmias), esmolol
hydrochloride (a beta adrenergic receptor blocker) was given
before pacing. After a 5-minute stabilization of sinus rate, a
three-burst-pacing (at 800 bpm) protocol was performed in
each animal of the paced group. Occurrence and duration of
rhythm disturbances were characterized by ECG (Figure 1).
The duration of induced self-terminating paroxysms of AF
was measured from the end of the last stimulus of the burst
pacing to the first P-wave upon spontaneous reversion to
normal sinus rhythm. Burst pacing was not performed in
the sham-operated group. Animals were euthanized 20–24
hours after cessation of pacing to harvest cardiac tissues
for RNA and protein isolation and histology. Animals were
used in accordance with the EuropeanCommissionDirective
86/609/EEC and all protocols were approved by the Insti-
tutional Animal Care and Use Ethics Committee (permit
number: CE 012/2012; University of La Corun˜a, La Corun˜a,
Spain).
2.2. Cell Culture and Transfection In Vitro. The mouse atrial
cardiomyocyte cell line, HL-1 (provided by ProfessorWilliam
C. Claycomb), was cultured in Claycomb’s growth medium.
HL-1 cells (6 × 105 cells per well) were transfected with
pre-miR-21 (Ambion, USA) and anti-miR-21 (Eurogentec,
Belgium) at 10–50 nMusing Lipofectamine 2000 (Invitrogen,
Barcelona, Spain) according to manufacturer’s guidelines.
Negative controls included nontransfected (mock) cells as
well as 5󸀠 carboxyfluorescein- (FAM-) labeled pre-miR nega-
tive control transfected cells, which also allowed transfection
efficiency evaluation. In each assay, transfections were per-
formed in triplicate. The transfection efficiency was around
60% in all experiments. After 4 hours of posttransfection,HL-
1 cells were cultured in fresh medium for 48 hours and then
harvested and processed for RNA and protein extraction as
described [44].
2.3. Microarray. Purification of total RNA, including small
RNAs, from LA samples was performed using miRNeasy
Mini Kit (Qiagen, USA), including the on-column DNase
digestion with RNase-free DNase, as described in the Qiagen
Manual. Deep-frozen LA samples were directly homogenized
in QIAzol lysis reagent (Qiagen) using a high-speed rotor-
stator homogenizer (Ultra-Turrax T8, Germany). RNA was
quantified by spectrophotometry and quality was evaluated
by gel electrophoresis. Microarray analysis of RNAs isolated
from LA biopsies of three paced and three sham pigs was per-
formed by a service provider (LC Sciences, Houston, USA)
using Pig miRNA Array (MRA-1013, version miRPig 20),
which contains 322 unique probes (9 repeats each) of pig
mature miRNAs. The probe content comes from version 20
of the miRBase sequence database which was updated on
June 24, 2013. Briefly, the detection probes were made by
in situ synthesis using PGR (photogenerated reagent) chem-
istry. Hybridization was performed overnight on a 𝜇Paraflo
microfluidic chip using a microcirculation pump (Atactic
Technologies). Fluorescence images were collected using a
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Figure 1: An electrical pacing assay. (a) Anaesthetized piglet (with automatic artificial lung ventilation) in the animal operating room. (b)
Placing a pacing catheter in the right atrium (RA) using fluoroscopic guidance. (c) Representative telemetry ECG recordings monitored
before, during, and after RA burst pacing.
laser scanner (GenePix 4000B, Molecular Device) and digi-
tized using Array-Pro image analysis software (Media Cyber-
netics). 𝑡-test was performed between control and exper-
imental sample groups. 𝑇-values were calculated for each
miRNA, and 𝑝 values were computed from the theoretical 𝑡-
distribution. The clustering was done using the hierarchical
method and performed with average linkage and Euclidean
distance metric. The complete microarray data is available at
NCBI through GEO (Gene Expression Omnibus) accession
number GSE65330 (http://www.ncbi.nlm.nih.gov/geo).
2.4. Real-Time Quantitative PCR (qRT-PCR). qRT-PCR was
performed on Bio-Rad IQ5 instrument (Bio-Rad, Madrid,
Spain) and MxPro Mx3005p qPCR thermal cycler (Strata-
gene, Madrid, Spain) using, respectively, SYBR Green (Bio-
Rad, Madrid, Spain) and Dynamo SYBR Green (Finnzymes,
Finland) master mix as described previously [44, 45]. The
primer pairs were located in different exons to rule out
genomic DNA amplification. Each primer pair used yielded a
single peak of dissociation on the melting curve and a single
band with the expected size on PAGE gels. Identity of the
PCR products was confirmed by sequencing. NT and non-
RT RNA template reactions were used as negative controls.
All PCR setups were performed at least in triplicate. Relative
quantifications were calculated with the comparative ΔCt
cycle method with normalization to the expression of house-
keeping genes coding for ribosomal protein L19 (Rpl19), 𝛽-
actin, glyceraldehyde-3-phosphate dehydrogenase (Gapdh),
and 𝛽-D-glucuronidase (Gusb). The efficiency of target and
reference amplifications was tested to be approximately
equal. miRNA qRT-PCR was performed using Exiqon LNA
microRNA qRT-PCR primers and detection kit (Exiqon,
Madrid, Spain) according to manufacturer’s guidelines. All
reactions were run in triplicate using 5S as normalizing
control. Primer sequences and additional data are available
upon request.
2.5. Antibodies. The following primary antibodies were used:
(1) rabbit polyclonal antibodies to PITX2A,B,C (Capra Sci-
ence, A¨ngelholm, Sweden; at 1 : 2000 dilution): the specificity
of the anti-PITX2 antibodies was independently validated
by Western blot analysis of COS-7 cells expressing each
PITX2 isoform [46]; (2) rabbit polyclonal antibodies to
TBX5 (Abcam, Cambridge, UK; at 1 : 500 dilution); (3) rabbit
polyclonal antibodies to myocardin which were generated
by Davids Biotechnologie (Regensburg, Germany) using the
recombinant TAD-containing fragment of porcine MYOCD
as immunogen (at 1 : 500 dilution): these antibodies were
shown to be specific for both MYOCD-A (minor) and
MYOCD-B (major) variants expressed in pig cardiac tissues
[47]; (4) rabbit polyclonal antibodies to cardiac troponin I
(Abcam, Cambridge, UK; at 1 : 40000 dilution); (5) rabbit
polyclonal antibodies to cardiac calsequestrin-2 (Abcam,
Cambridge, UK; at 1 : 10000 dilution); (6) rabbit monoclonal
antibodies to sarcoplasmic reticulum ATPase (SERCA-2A;
Abcam, Cambridge, UK; at 1 : 10000 dilution); (7) rabbit
polyclonal antibodies to caspase-3 (Cell Signaling, Leiden,
Netherlands; at 1 : 1000); (8) rabbit monoclonal antibodies
to caspase-9 (Abcam, Cambridge, UK; at 1 : 1000 dilution);
and (9) mouse monoclonal anti-GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) antibody (Sigma, Madrid, Spain;
at 1 : 10000 dilution). Secondary peroxidase conjugated anti-
rabbit and anti-mouse IgG (Fab-specific) antibodies were
purchased from Sigma (Madrid, Spain).
2.6. SDS-PAGE and Western Blotting. Tissue samples were
homogenized in standard 2x Laemmli buffer (Invitrogen,
Barcelona, Spain) supplemented with complete protease
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inhibitor cocktail (Roche, Madrid, Spain) as previously
described [45, 46]. Following centrifugation at 20000 g
for 30 minutes, the concentration of supernatant proteins
was analyzed using the Bio-Rad DC Protein Assay Kit
(Bio-Rad, Hercules, USA) according to the manufacturer’s
protocol. The protein extracts were normalized to total
protein concentration; the results of normalization were
confirmed by SDS-PAGE and Coomassie staining before
Western blotting analysis [46]. Protein supernatants (loading
range of 5–15mg/run) were resolved on a 12% SDS-PAGE
(Mini-Protean-III, Bio-Rad, Hercules, USA) and blotted
onto PVDF-membranes (Hybond-P, Amersham Biosciences,
Barcelona, Spain). Molecular weight (MW) standards (Pre-
cision Plus Protein WesternC Standards from Bio-Rad and
SeeBlue Plus2 Pre-Stained Standard from Invitrogen) were
included on each gel. Blots were probed with the antibodies
indicated above and visualized by the Super-SignalWest Pico
chemiluminescent substrate (Pierce Biotechnology, Madrid,
Spain). Equivalence of protein loading was confirmed by
Amido Black 10B (Merck, Barcelona, Spain) staining of
blots after immunodetection. The blots were reprobed with
anti-GAPDH antibodies as additional control for loading.
Quantification of Western blot signals was obtained by using
a Bio-Rad GS800 calibrated densitometer with Quantity One
software.
2.7. Histochemical Staining. Fragments of LA samples were
fixed with 4% paraformaldehyde (in PBS, 1 hour at room
temperature), paraffin-embedded, 5𝜇m sectioned, stained
with Picrosirius Red (Sigma,Madrid, Spain) as described pre-
viously [48], and visualized with bright-field “Nikon Eclipse
600” microscopy by an experienced technician blinded to
the experimental design. The area of red-stained pixels was
quantified in three zones of LA free wall sections from three
paced versus three sham animals by ROI (Region of Interest)
analysis using ACT-2U Image software (version 1.4, Nikon,
Japan).
2.8. Statistical Analysis. Values are expressed as mean ±
S.E.M. All comparisons between groups were performed
using unpaired Student’s 𝑡-test. Differences were considered
statistically significant for 𝑝 value ≤ 0.05.
3. Results
3.1. Burst Tachypacing Results in Self-Terminating Paroxysms
of Atrial Fibrillation. Brief self-terminating episodes of AF
were induced in postnatal pigs by repetitive burst pacing of
the RA via an implanted catheter electrode (see Figure 1).
Hemodynamic parameters were comparable in the paced
versus sham animals throughout the experiment. Before and
after catheter insertion, the ventricular rate means were
similar at baseline in both sham and pacing groups but
increased in the pacing group compared with baseline upon
electrical stimulation (150 ± 6 bpm versus 130 ± 3 bpm).
Every burst was followed by consecutive (3–5) AF episodes,
each lasting 20–30 sec. On average, a total duration of AF
episodes (per animal) was 600 ± 120 sec. No AF episodes
were detected by ECG-tracing at least 1 hour after the tach-
yarrhythmia protocol was terminated. On the next day, the
ECG examination (prior to sacrifice of animals and excision
of the heart) showed normal heart rhythm (with normal
QRS duration) in both paced and sham pigs. Picrosirius red
staining revealed no signs of fibrosis in LA samples from
paced or sham animals (data not shown).
These results suggest that episodes of self-terminating
AF observed in our porcine model are reminiscent of those
which occur in patients with asymptomatic paroxysmal AF.
3.2. Paroxysmal Atrial Tachyarrhythmia Leads to a Rapid
Change in Atrial miRNA Transcriptome. Since the RA might
have been damaged by catheter insertion, we studied miRNA
expression changes associated with AF in the LA from paced
versus sham pigs 20–24 hours after pacing. Our initial goal
was to analyze AF-inducedmiRNA transcriptome changes by
microarray approach. The results of microarray experiments
demonstrated that transient episodes of AF alter the miRNA
expression profiles of the LA. Of 322 porcine mature miRNA
sequences analyzed by microarrays, the expression of 29
miRNAswas significantly up- (12miRNAs) or downregulated
(17 miRNAs) in the LA from paced versus sham animals
(Figure 2; Table 1). Seven miRNAs (i.e., miR-7140-3p, miR-
4335, miR-129b, miR-296-5p, miR-4334-5p, miR-4339, and
miR-182) showed 2-fold or greater increases after LA pacing.
The biggest difference was observed for miR-7140-3p, which
was expressed approximately 4-fold higher in paced than
in sham animals. The known cardiac-expressed miRNAs
(i.e., miR-24-2-5p, miR-542-5, miR-27b-5p, miR-7, and miR-
30c-3p; see Table 1) were prominent among the miRNAs
that showed a significant downregulated expression (∼2-fold
decrease) in the paced group compared with controls. Of
particular note, the microarray profiling unveiled a low-to-
moderate downregulation of threemiRNAs (i.e., miR-143-3p,
miR-363, and miR-18b) previously detected in patients with
chronic AF. Pacing-induced alterations in the expression of
other miRNAs with particular concern for their involvement
in AF could not be determined by microarray hybridizations
due to a high variability among replicates (miR-1, miR-21,
miR-23a/b,miR-29a, andmiR-133a) or very lowhybridization
signals (miR-10a, miR-10b; see the complete microarray data
at NCBI through GEO accession number GSE65330).
Consequently, our second goal was to study whether the
expression of these and other AF-associated miRNAs (not
revealed by microarray evaluation) could be altered in our
porcine model. To this end, the expression of 11 miRNAs,
selected on the basis of published reports [7–9, 13, 14, 21] (and
references wherein), was analyzed by qPCR in the LA from
paced versus sham pigs (Figure 3). Six miRNAs (miR-1, miR-
10a-5p, miR-10b, miR-21, miR-29a, and miR-208a) showed
a higher expression in paced as compared with nonpaced
animals. The expression of miR-23a, miR-23b, and miR-24
was significantly reduced following pacing, while that ofmiR-
133a, miR-125-3p, and miR-141 remained unchanged.
Taken together, the results indicate that short-term atrial
tachyarrhythmia episodes lead to a rapidmiRNA remodeling
of atrial myocardium.
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Table 1: The miRNAs significantly up- or downregulated in the paced LA, ordered by the fold change (FC).
miRNA FC Direction 𝑝 value Reported expression in∗ Reference
ssc-miR-7140-3p 3,92 Up 0,0199 Porcine lung [25]
ssc-miR-4335 3,22 Up 0,0540 Porcine intestine [26]
ssc-miR-129b 2,90 Up 0,0520 Catfish heart [27]
ssc-miR-296-5p 2,35 Up 0,0530 Human placenta [28]
ssc-miR-4334-5p 2,22 Up 0,0072 Porcine intestine [26]
ssc-miR-4339 2,16 Up 0,0499 Porcine intestine [26]
ssc-miR-182 2,13 Up 0,0021 Human skeletal muscles [29]
ssc-miR-4332 1,95 Up 0,0339 Porcine intestine [26]
ssc-miR-1249 1,90 Up 0,0550 Rat pancreas [30]
ssc-miR-1307 1,83 Up 0,0542 Human blood cells [31]
ssc-miR-671-3p 1,63 Up 0,0492 Human atria [23]
ssc-miR-423-3p 1,61 Up 0,0025 Rat hippocampus [32]
ssc-miR-23b −1,10 Down 0,0146 Human atria, AF [20]
ssc-miR-22-3p −1,19 Down 0,0181 Human atria, AF [20]
ssc-miR-143-3p −1,26 Down 0,0402 Human atria, AF [20]
ssc-miR-324 −1,30 Down 0,0050 Human blood cells [33]
ssc-miR-455-5p −1,42 Down 0,0551 Human meningeal arteries [34]
ssc-miR-326 −1,46 Down 0,0546 Human brain tissues [35]
ssc-miR-362 −1,57 Down 0,0069 Human skeletal muscles [36]
ssc-miR-363 −1,62 Down 0,0069 Human atria, AF [21]
ssc-miR-18b −1,67 Down 0,0550 Human atria, AF [21]
ssc-miR-17-3p −1,68 Down 0,0336 Mouse heart [37]
ssc-miR-24-2-5p −1,79 Down 0,0187 Human atria, AF [23]
ssc-miR-542-5p −1,85 Down 0,0318 Human atria, AF [23]
ssc-miR-486 −1,88 Down 0,0365 Mouse skeletal muscles [38]
ssc-miR-27b-5p −1,96 Down 0,0509 Human atria, AF [23]
ssc-miR-7 −2,37 Down 0,0211 Porcine heart [39]
ssc-miR-30c-3p −2,55 Down 0,0345 Porcine heart [39]
ssc-miR-381 −2,69 Down 0,0540 Human skeletal muscles [40]
∗Except the expression in malignant tumors and model cell lines. Bold, detected in AF patient samples.
3.3. Paroxysmal Atrial Tachyarrhythmia Leads to Downregu-
lation of Transcriptional Factors Related to Atrial Arrhythmia
Susceptibility. TFs, such as Pitx2 and Tbx5, are increas-
ingly recognized as potentially important contributors to
atrial arrhythmia susceptibility (recently reviewed in [42]).
Enlargement of the LA is widely regarded to be an epidemi-
ological risk indicator for AF, and a transcription cofactor,
myocardin (Myocd), has been identified as a possible suscep-
tibility gene affecting LA size and function [43]. Our objective
in this regard was to study whether these genes (with
potential roles in arrhythmogenesis) are involved in early
response of LA myocardium to induction of paroxysmal-like
AF.
We evaluated transcript levels of Pitx2, Tbx5, andMyocd
in the LA myocardium from paced versus nonpaced control
pigs by qRT-PCR (Figure 4(a)). While the level of Myocd
mRNA expression was reduced following pacing, Pitx2 and
Tbx5 remained statistically unchanged between control and
paced groups. At the protein level, however, a marked decline
in expression of not only Myocd but also Pitx2 and Tbx5
was revealed in the LA of paced animals by Western blot
(Figure 4(b)).
Signs of increased apoptosis were detected in atrial tissue
in the canine tachypacing model of AF [49]. In this sense,
the possibility that apoptosis might be responsible for the
observed Pitx2, Tbx5, and Myocd protein downregulation
could not be excluded. Western blot analysis did not reveal
differences in LA expression levels of pro-caspase-3 and pro-
caspase-9 between paced and control pigs, nor signs of acti-
vation of these key apoptotic enzymes in any of LA samples
studied. In addition, LA levels of cardiac calcium-handling
proteins (calsequestrin-2 and sarcoplasmic reticulum Ca2+
ATPase) and troponin I were not affected by pacing per se
(Figure 4(b)). Therefore, it is doubtful that apoptosis is the
principal factor responsible for the observed Pitx2, Tbx5, and
Myocd protein downregulation in the LA following pacing.
It then became our working hypothesis that inhibition
of translation by miRNAs can be responsible, at least in
part, for the decrease in protein expression of Pitx2, Tbx5,
and Myocd in paced pigs. There is growing evidence that
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Figure 2: MicroRNA microarray expression profiling of the left
atrium from paced versus nonpaced pigs. Heat map of the most
differentially expressed (statistically significant) miRNAs in the left
atrium of three paced (4–6) compared to three sham (1–3) animals.
Relative expression is log
2
.
miRNAs induce gene silencing with translational repression
occurring first and then followed by mRNA decay (reviewed
in [50, 51]). Our qPCR analysis showed that pacing resulted in
a significant upregulation of a set of AF-associated miRNAs
(i.e., miR-1, miR-10a, miR-10b, miR-21, miR-29a, and miR-
208a) in the LA compared with the control (see Figure 3).
Computational analysis (by miRanda and Targetscan) of
the 3󸀠 untranslated region of pig Pitx2, Tbx5, and Myocd
genes revealed consensus sites for binding of, respectively,
miR-21, miR-10a/miR-10b, and miR-1 (Figure 5(a)). Some of
these predictedmiRNA/mRNA pairings were in line with the
available experimental evidence. In transfection assays, miR-
1 inhibits mouseMyocd expression at the transcript [52] and
protein level [53], while bothmiR-10a andmiR-10b negatively
modulate human Tbx5 expression at the protein level [54].
In this study, we attempted to validate, for the first time,
whethermiR-21 can alter Pitx2 expression in a cardiomyocyte
background. To this end, miR-21 mimic and anti-miR-21
inhibitor were transfected into atrial HL-1 cardiomyocytes
and the expression of Pitx2c gene was detected by qRT-PCR
and Western blot (Figures 5(b), 5(c), and 5(d)). Transfection
of HL-1 cardiomyocytes with miR-21 mimic silenced Pitx2c
expression to a certain, but statistically significant, extent,
whereas anti-miR-21 induced a marked increase in the
Pitx2c transcript without affecting the expression of Mef2c
(myocyte enhancer factor 2c) TF. Of note, endogenous miR-
21, abundantly expressed inHL-1 cells [55],may interferewith
Pitx2-silencing by miR-21 mimic transfection. An efficient
Pitx2c activation by anti-miR-21, as observed in transfection
assays, is concordant with this suggestion. A complimentary
Western blot analysis (Figures 5(c) and 5(d)) revealed that
PITX2C protein levels were significantly decreased in miR-
21 transfected cells, being only slightly upregulated after
anti-miR-21 delivery. The latter could probably be the result
of additional mechanisms influencing the Pitx2c transcript
versus protein ratio in anti-miR-21 transfected cells.
Consistent with the results obtained and other reports
[53, 54], the histogram plot (Figure 5(e)) exhibits a clear
inverse correlation in the protein expression of Pitx2 versus
miR-21, Tbx5 versus miR-10b, andMyocd versus miR-1 in the
LA of paced animals, confirming thus our hypothesis.
Together these data show that sporadic AF paroxysms are
associatedwithmarkeddownregulation of theseTFs involved
in AF susceptibility of atrial myocardium.
4. Discussion
In this study we provide evidence for two major findings.
On the one hand, self-terminating paroxysms of AF caused
a rapid and substantial miRNA remodeling of the LA
myocardium in our animal model. On the other hand, this
miRNA remodeling is associated with amarked downregula-
tion of Pitx2, Tbx5, andMyocd TFs in paced atria.
The expression of 38 miRNAs was significantly altered
due to burst pacing-induced paroxysms of AF, as revealed by
microarray (29 miRNAs, see Table 1) and qPCR analysis (9
miRNAs, see Figure 3), and this number is obviously superior
to that found inmicroarray study of LA samples frompatients
with paroxysmal AF (10 miRNAs [24]). They can be divided,
in terms of expression patterns, into three categories as (1)
miRs that have not previously been reported as expressed in
the heart, (2) miRs with known expression in cardiac and
skeletal muscles but not yet associated with AF, and (3) miRs
with well-established AF-associated expression. Although
this is by no means an exclusive list, it certainly contains
some of the promising miRs to be further evaluated for their
potential in AF. Of particular note, in this context, are miR-
182 and miR-486, which were found to attenuate atrophy-
related gene expression in skeletal muscle [38, 56]. Albeit the
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Figure 3: Expression of AF-associated miRNAs in the left atrium from paced (EXP) versus nonpaced (CON) pigs as revealed by qRT-PCR
analysis. ∗𝑝 ≤ 0.05 (𝑛 = 5 for each group).
assayed tissue was skeletal muscle, both these miRs target
the FoxO1 TF which has an important function in mediating
apoptosis in the heart [57]. AF is strongly associated with
changes in the heart that occur with aging (reviewed in [58]).
In this respect, miR-17-3p (see Table 1), a negative modulator
of cardiac aging [37], would also be a good candidate to be
studied for a potential AF meaning.
The expression signature of known AF-associated miR-
NAs in our model of paroxysmal-like AF (bold-marked in
Table 1 and listed in Figure 3) appears to be different from that
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found in chronic AF in patients and animal models. Down-
regulation of miR-1, miR-10a, miR-29a, and miR-208a has
been implicated in chronicAF [7, 13, 59], while thesemiRNAs
were highly upregulated in the porcine LA in response to
brief paroxysms of AF. In the same way, the levels of miR-
133 expression significantly downregulated in chronic AF
[13, 14] were unchanged in our model. Upregulation of miR-
18b and miR-363 was found to be associated with chronic AF
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in patients [21], albeit these miRNAs were downregulated in
paced pigs (see Table 1). Overall, it is tempting to speculate
that the expression of the same set of AF-associated miRNAs
can be up- or downregulated as a function of progression
fromparoxysmal to chronicAF.What is of note in this regard,
however, is that the expression of miR-22-3p, miR-23b, and
miR-143-3p was similarly downregulated in both patients
with chronic AF [20] and our paroxysmal-like AF model
(see Table 1). Likewise, expression of miR-21 was upregulated
in the LA of patients with long-term persistent AF [60], as
well as after short-term AF in pigs (this work). These results
suggest that the expression of a subgroup of AF-associated
microRNAs could be similarly altered in both paroxysmal
and chronic AF states, indicating that congruent miRNA
remodeling may occur within different AF contexts.
There are a few data [23, 24] which instead suggest that
microRNA remodeling is quite distinct in paroxysmal AF in
comparison with that in chronic AF. In one of these reports
[23], RA biopsies were obtained from hypertonic patients
with paroxysmal AF secondary to or associated with organic
heart diseases, suggesting that the observed alterations in
miRNA expression may have been attributable to the under-
lying heart disease rather than paroxysmal AF per se. In the
other study [24], patients with paroxysmalAF had no obvious
clinical signs of cardiovascular disease but LA biopsies
taken from them for miRNA microarray analysis showed
a markedly increased fibrosis as compared to those from
patients with sinus rhythm. Our study is advantageous to the
above-mentioned reports in the sense that we performed the
miRNA microarray analysis, using LA biopsies from paced
animals without pathological cardiovascular background. In
addition, biochemical and histochemical analyses did not
reveal signs of proapoptotic and profibrotic activation in
paced atrial samples.
An aspect of particular interest of our study was the
finding that the upregulation of miR-1, miR-10a, miR-10b,
and miR-21 is negatively correlated with downregulation
of, respectively, MYOCD, TBX5, and PITX2c in the paced
LA (see Figure 5(e)). The results of transient transfection
assays demonstrated that (1) miR-21 negatively regulates the
expression of Pitx2c (this work), (2) miR-1 suppressesMyocd
expression [53], and (3) miR-10a and miR-10b both inhibit
Tbx5 expression [54]. The functional relevance of these
miRNA/TF relations (established through our model) to AF
development remains elusive and thus future experimental
approaches using knockdown and overexpression strategies
are highly desirable.
There are lines of evidence that implicate downregulated
expression of Pitx2, Tbx5, and, probably, Myocd in a predis-
position toAF progression. In fact, several studies revealed an
association between LA Pitx2 downregulation and increased
atrial arrhythmogenicity (reviewed in [61]). More recent
research implicates Pitx2 and Pitx2-mediated signaling in
prevention of AF [62, 63]. In some patients with Holt-Oram
syndrome and AF, the disease is caused by Tbx5 mutations
that create a premature termination codon,which is predicted
to result in haploinsufficiency. It should be noted, however,
that increased Tbx5 dosage (gain-of-functionmutations) was
also associated with Holt-Oram syndrome and paroxysmal
AF (reviewed in [41, 42]).Myocd is regarded as themost likely
candidate among the genes affecting LA size [43], which is
a clinical marker for risk stratification of AF development
[64]. Cardiac-restricted inactivation of theMyocd gene in the
adult heart resulted in development of severe four-chambered
heart failure as a result of massive myocyte loss via apoptosis
and replacement fibrosis (reviewed in [65, 66]).
The proarrhythmogenicmechanisms leading to the spon-
taneously self-terminating AF episodes typical of patients
with paroxysmal AF remain elusive and not yet studied as
hoped. Our results provide suggestive evidence for a signif-
icant Pitx2, Tbx5, and Myocd downregulation in a specific
microRNA-upregulation context in response to tachycardia-
induced AF. From this perspective, our data would suggest
that higher levels of miR-21, miR-10b, and miR-1 in the
LA myocardium contribute to arrhythmogenesis via per-
turbation of Pitx2, Tbx5, and Myocd signaling pathways,
respectively.
5. Conclusions
In conclusion, we herein demonstrate that even short-lasting
atrial tachyarrhythmia is associated with significant miRNA
remodeling coupled with decreased expression of TFs with
potential roles in arrhythmogenesis. We propose that the
downregulation of Pitx2c, Tbx5, and Myocd may be permis-
sive for future AF development. This study provides, there-
fore, previously unknown insights into interrogatingmiRNA-
TF regulations underlying paroxysmal AF development in a
large animal model, with potentially important implications
from a biomedical perspective.
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